Search results for " onj"
showing 10 items of 12 documents
Latvijas Vēstures Institūta Žurnāls. 2022, Nr. 1 (115)
2022
LU Latvijas vēstures institūta LU ilgtermiņa saistību izpildei 2020.-2022. g. ("Latvijas Vēstures Institūta Žurnāls")
MRONJ in breast cancer patients under bone modifying agents for cancer treatment-induced bone loss (CTIBL): a multi-hospital-based case series
2023
Abstract Background Cancer treatment-induced bone loss (CTIBL) is the most common adverse event experienced by patients affected by breast cancer (BC) patients, without bone metastases. Bone modifying agents (BMAs) therapy is prescribed for the prevention of CTIBL, but it exposes patients to the risk of MRONJ. Methods This multicentre hospital-based retrospective study included consecutive non-metastatic BC patients affected by MRONJ related to exposure to low-dose BMAs for CTIBL prevention. Patients’ data were retrospectively collected from the clinical charts of seven recruiting Italian centres. Results MRONJ lesions were found in fifteen females (mean age 67.5 years), mainly in the mandi…
Development of OloHealth, a teledentistry platform for the ONJ prevention in Sicily: preliminary reports
2018
Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. A Commentary of the Pivotal Trial by Raje et al. Published on La…
2018
The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on incidence, diagnosis, and follow-up of osteonecrosis of the jaw (ONJ) cases, observed among treated patients. Adopted definition to adjudicate ONJ cases, type of registration of potential ONJ cases, length of observation are possible causes of potential underestimation of ONJ incidence in their study. Future updated evaluations with longer follow-up, and including actuarial estimation, are required…
Ozone Infiltration for Osteonecrosis of the Jaw Therapy: A Case Series
2022
Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse reaction, mainly due to bone-modifying agents (BMA), and it is a potentially painful and debilitating condition. To date, the literature has reported a 90% rate of successful outcomes for MRONJ patients undergoing surgical treatment. Particularly for patients with advanced disease stages who are unsuitable for surgery, prolonged medical treatment is required, with a consequent risk of the overuse of antibiotics and antibiotic resistance. The aim of this study is to evaluate the efficiency and safety of ozone, via oral mucosal infiltrations, in seven cancer patients with MRONJ, who are not eligible for surgery. The prot…
Pain management in osteonecrosis of jaw (ONJ): an orphan issue?
2018
We performed a systematic review of oNJ literature with keyword and MeSH terms referred to pain and its treatment, on PubMed and other literature sources on 2014-2018 years. out of 2957 publications citing oNJ and published in the period, 350 papers reported about pain anyhow.
Healing evaluation by means of Optical Coherence Tomography of an extraction socket with L-PRF application in a patient at ONJ risk: a case report
2016
CAPITOLO I. OSTEONECROSI DELLE OSSA MASCELLARI (ONJ) FARMACO-RELATA
2020
Si definisce osteonecrosi delle ossa mascellari associata a bisfo- sfonati e/o altri farmaci una “reazione avversa farmaco-correlata, caratterizzata dalla progressiva distruzione e necrosi dell’osso mandibolare e/o mascellare di soggetti esposti al trattamento con farmaci per cui sia accertato un aumentato rischio di malat- tia, in assenza di un pregresso trattamento radiante”. In Tabella. 1.1 sono riportati i relativi criteri di inclusione, di esclusione e di dubbio.
LA GESTIONE ODONTOIATRICA DEL PAZIENTE CHE ASSUMERÀ O ASSUME FARMACI ONJ-RELATI
2020
L’osteonecrosi delle ossa mascellari (ONJ) farmaco-relata è stata de- finita nel capitolo I come “una reazione avversa farmaco-correlata, caratterizzata dalla progressiva distruzione e necrosi dell’osso man- dibolare e/o mascellare di soggetti esposti al trattamento con farmaci per cui sia accertato un aumentato rischio di malattia, in assenza di un pregresso trattamento radiante”1. Tale definizione sottolinea la consapevolezza di uno stato di allerta e di vigilanza sui fattori di ri- schio associati alla patologia, con la possibile progressiva inclusione di nuove popolazioni di soggetti potenzialmente a rischio, e in linea con la continua evoluzione delle conoscenze scientifiche in materia…